Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals.
Lai A, Violin M, Ebranati E, Franzetti M, Micheli V, Gismondo MR, Capetti A, Meraviglia P, Simonetti FR, Bozzi G, Ciccozzi M, Galli M, Zehender G, Balotta C. Lai A, et al. Among authors: micheli v. AIDS Res Hum Retroviruses. 2012 Aug;28(8):857-65. doi: 10.1089/aid.2011.0245. Epub 2011 Nov 22. AIDS Res Hum Retroviruses. 2012. PMID: 21936750 Free PMC article.
Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients.
Perrone V, Cattaneo D, Radice S, Sangiorgi D, Federici AB, Gismondo MR, Medaglia M, Micheli V, Vimercati S, Pallone E, Degli Esposti L, Clementi E. Perrone V, et al. Among authors: micheli v. Clinicoecon Outcomes Res. 2014 Jul 14;6:341-8. doi: 10.2147/CEOR.S58036. eCollection 2014. Clinicoecon Outcomes Res. 2014. PMID: 25053888 Free PMC article.
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.
Rossotti R, Borghi V, Callegaro AP, Micheli V, Bruzzone B, Colao G, Gismondo MR, Vicenti I, Penco G, Zazzi M, Rusconi S. Rossotti R, et al. Among authors: micheli v. J Clin Virol. 2016 Oct;83:48-53. doi: 10.1016/j.jcv.2016.08.293. Epub 2016 Aug 23. J Clin Virol. 2016. PMID: 27591555
Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, Torre A, Cossu MV, Minari C, Ballone E, Perotti A, Mileto D, Niero F, Merli S, Foschi A, Vimercati S, Rizzardini G, Sollima S, Bradanini L, Galimberti L, Colombo R, Micheli V, Negri C, Ridolfo AL, Meroni L, Galli M, Antinori S, Corbellino M. Morena V, et al. Among authors: micheli v. Eur J Intern Med. 2020 Jun;76:36-42. doi: 10.1016/j.ejim.2020.05.011. Epub 2020 May 21. Eur J Intern Med. 2020. PMID: 32448770 Free PMC article.
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.
Armenia D, Bouba Y, Gagliardini R, Gori C, Bertoli A, Borghi V, Gennari W, Micheli V, Callegaro AP, Gazzola L, Bruzzone B, Giannetti A, Mazzotta V, Vergori A, Mastrorosa I, Colafigli M, Lichtner M, di Biagio A, Maggiolo F, Rizzardini G, d'Arminio Monforte A, Andreoni M, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM; Italian INI-Surveillance Group. Armenia D, et al. Among authors: micheli v. J Clin Virol. 2020 Sep;130:104534. doi: 10.1016/j.jcv.2020.104534. Epub 2020 Jul 11. J Clin Virol. 2020. PMID: 32769022 Free article.
244 results